-
Mashup Score: 35MedNews Week - 1 day(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Chandler Park, M.D., F.A.C.P. on LinkedIn: #harryyoon #thachgiaotruong #maxwellkrem #jessicageiger #inspire… - 5 day(s) ago
⭐️What a FUN precision medicine and immunotherapy meeting at Cleveland Clinic Thank you to my good friend Shilpa Gupta, MD for co-moderating this incredible…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Yan Leyfman: ASCO Breakthrough was an unparalleled experience / ASCO, cacner advances, cancer, Cancer research, clinical trials, Julie Gralow, Lynn Schuchter,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 412023 Year in review: Early breast cancer - 2 month(s) ago
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adjuvant CDK4/6 inhibitors was observed in high-risk hormone receptor-positive disease and the addition of immunotherapy to neoadjuvant chemotherapy improved pathological response. Continued benefit from perioperative pembrolizumab was reported in patients with triple negative breast cancer, while atezolizumab did not improve the risk of recurrence either pre- or postoperatively.
Source: www.thebreastonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18MedNews Week - 5 month(s) ago
Connecting audiences with high quality, current medical information in the fight against misinformation. Follow Us to Stay Connected & Updated! Clubhouse: https://www.clubhouse.com/house/mednews-week Linktr.ee: https://linktr.ee/themednewsweek?subscribe LinkedIn: https://www.linkedin.com/company/mednewsweek Tik Tok: https://www.tiktok.com/@mednewsweek?lang=en Twitter: https://twitter.com/MedNewsWeek VuMedi: https://www.vumedi.com/channel/mednews-week/ Website: http://mednewsweek.com
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 8 - Oncodaily | Oncology News, Insights, Stories - 7 month(s) ago
Once again, it’s Saturday, and we continue OncoDaily’s series, ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2023.’ As
Source: oncodaily.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8Oligometastatic Bladder Cancer: Defining a Novel Entity - 7 month(s) ago
Over the past decade, there has been substantial progress in the therapeutic management of patients with metastatic bladder cancer (BCa), notably with the recent emergence of immune checkpoint inhibitors and antibody-drug conjugates [1]. From a translational standpoint, molecular subtypes of BCa characterized by specific expression profiles have been identified and can potentially predict distinct clinical and therapeutic outcomes, although with a lack of prospective validated relevance in the clinic [2].
Source: www.europeanurology.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 110Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial - 7 month(s) ago
Nature Medicine – In a phase 2 trial, the combination of gemcitabine, cisplatin and anti-PD-1 led to a clinical complete response in 43% of patients with muscle-invasive bladder cancer, which…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10
Abstract. Purpose: The MORPHEUS platform was designed to identify early efficacy signals and evaluate the safety of novel immunotherapy combinations across cancer types. The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced or metastatic (mUC). Additional treatment combinations were evaluated and will be reported separately. Patients and Methods: Patients had locally advanced or mUC that progressed during or following treatment with a platinum-containing regimen. The primary efficacy endpoint was investigator-assessed objective response rate (ORR). Key secondary endpoints included investigator-assessed progression-free survival (PFS) and overall survival (OS). Safety and exploratory biomarker analyses were also conducted. Results: Seventy-six patients were randomized to receive either atezolizumab plus magrolimab (n=16), atezolizumab plus niraparib (n=15), atezolizumab plus tocilizum
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 23The OncoAlert Newsletter is NOW OUT Click to Register - 8 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Hem/Oncs, Latest HeadlinesTweet
⭐️Thank you Dr. Singhi @esinghimd for joining us @MedNewsWeek on @OncLive and sharing your compelling journey to become a Thoracic Oncologist @MDAndersonNews . @JackWestMD @StephenVLiu @ADesaiMD @YLeyfman @jacobadashek 👇Full video click👇 https://t.co/yeaheANXi5 https://t.co/MP0gXFafHx